On the morning of January 10, the atmosphere at the Radisson Hotel in Xinxiang International Conference Center was both lively and solemn. Representatives from universities and enterprises, along with distinguished guests, gathered for the "Release of Xinxiang City's 'Ten Measures' to Deepen University-Enterprise-Local Cooperation and the Centralized Signing Ceremony for Collaborative Projects." Li Wei, General Manager of EMICRO Biomedicine Company, and Jin Jianxin, Deputy General Manager, took the stage to sign agreements on behalf of Henan Normal University and EMICRO Biomedicine Company, respectively.  

On September 27, 2024, EMICRO Biomedicine made significant progress in the research and development of innovative drugs.

In order to strengthen the party organization construction and corporate culture work of non-public enterprises in the new era, Zhang Jie, deputy general manager of Wang's Group and chairman of the trade union, led a team on the morning of July 24, and some party members and propaganda backbones from the group office and affiliated enterprises went to Weihua Group, a "national advanced unit of corporate culture" in Changyuan City, for a visit, study and exchange activity.

On July 16, 2024, it was learned from Peking University Cancer Hospital that the Phase I clinical trial of the innovative anti-tumor drug BTK inhibitor TM471-1 capsule developed by EMICRO Biomedicine Company has passed the ethical review of the hospital's ethics committee and obtained ethical review approval.

On April 26, 2024, the launch ceremony of the "Financial Gathering Room" and the biopharmaceutical health industry finance docking meeting of Henan Academy of Medical Sciences at Zhengzhou Airport were held as scheduled. Yang Yinke, Chief Medical Officer of Henan Zhimei Biotechnology Co., Ltd., and Jin Jianxin, Deputy General Manager, were invited to lead the team and give a roadshow on the "Research and Development Project of Innovative Drug BTK Inhibitor TM471-1", which attracted the attention of the attending representatives and experts and was favored by multiple investment institutions.